KR20180079136A - Compositions for Anti-Avian influenza virus, SARS, MERS, Coronavirus by micro encapsulized natural herbs - Google Patents
Compositions for Anti-Avian influenza virus, SARS, MERS, Coronavirus by micro encapsulized natural herbs Download PDFInfo
- Publication number
- KR20180079136A KR20180079136A KR1020160184595A KR20160184595A KR20180079136A KR 20180079136 A KR20180079136 A KR 20180079136A KR 1020160184595 A KR1020160184595 A KR 1020160184595A KR 20160184595 A KR20160184595 A KR 20160184595A KR 20180079136 A KR20180079136 A KR 20180079136A
- Authority
- KR
- South Korea
- Prior art keywords
- avian influenza
- coronavirus
- sars
- mers
- oregano
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
- A01N25/26—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests in coated particulate form
- A01N25/28—Microcapsules or nanocapsules
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N65/00—Biocides, pest repellants or attractants, or plant growth regulators containing material from algae, lichens, bryophyta, multi-cellular fungi or plants, or extracts thereof
- A01N65/08—Magnoliopsida [dicotyledons]
- A01N65/22—Lamiaceae or Labiatae [Mint family], e.g. thyme, rosemary, skullcap, selfheal, lavender, perilla, pennyroyal, peppermint or spearmint
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Dentistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Alternative & Traditional Medicine (AREA)
- Plant Pathology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Agronomy & Crop Science (AREA)
- Toxicology (AREA)
- Pest Control & Pesticides (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
본 발명은 조류독감, SARS, MERS, 코로나바이러스등 바이러스를 억제 및 살균하는 천연 허브의 조성법에 관한 것으로, 보다 상세하게는 친환경 미세캡슐화 기술을 이용하여 각종 유행성 전염병에 있어서의 방역, 방제할 수 있도록 한 천연 허브로 제조된 방역제재의 조성법에 관한 것이다.The present invention relates to a method for preparing a natural herb that inhibits and sterilizes viruses such as avian influenza, SARS, MERS, coronavirus, and the like. More particularly, the present invention relates to a method for preventing and sterilizing various pandemic infectious diseases using environmental microencapsulation technology And to provide a method for preparing a nasal herb prepared with a natural herb.
천연 오레가노 허브는 강력한 천연 항생제라고 불리우는 고기능의 허브로서 서양의 고대 때부터 복통, 호흡기질환등의 치료에 사용이 되어 왔으며, 지중해 국가에서는 육류 저장에 있어 천연 방부제로서 사용을 해 오고 있다.The natural oregano herb is a high-performance herb called a powerful natural antibiotic and has been used since ancient times in ancient times for the treatment of abdominal pain and respiratory diseases and has been used as a natural preservative in meat storage in the Mediterranean countries.
Journal of Applied Pharmaceutical Science의 논문(ISSN: 2231-3354)에 따르면 오레가노 오일은 이미 해외의 다양한 논문으로서 각종 인풀루엔자(influenze) 바이러스에 대해 그 억제력, 항균력이 보고되어 지고 있다.According to the Journal of Applied Pharmaceutical Science (ISSN: 2231-3354), oregano oil has already been reported in various foreign countries, and its inhibitory and antibacterial activity against various influenza viruses has been reported.
그러나 이런 천연허브 오일은 오일의 기화하는 성질로서 그 효과가 오래 지속이 되기 힘들어 상용화에는 문제가 있기 때문에 실질적으로 각종 바이러스등에 유효하게 사용이 되어지려면 오일의 기화문제를 해결하여 효과가 오래 지속이 되게 할 필요성이 있다. However, such natural herbal oil is a vaporized nature of oil, and since its effect is not long lasting, it is problematic in commercialization. Therefore, in order to be effectively used for various viruses, it is necessary to solve the vaporization problem of oil, There is a need to do.
그래서 현재까지는 조류독감등의 전염병 확산시 강력한 독성의 화학물질로서 방역방제를 하고 있는데 이는 자연 파괴의 심각한 행위로서 보다 천연적이고 친환경적인 해결 방법이 필요로 되고 있다.So far, the spread of infectious diseases such as avian influenza is a powerful toxic chemical that is being controlled to prevent the spread of natural destruction is a serious act, more natural and environmentally friendly solution is needed.
이를 해결하기 위한 수단으로, 하기의 선행기술문헌에 나타난 바와 같이 다양한 조성법을 제공하여 이를 해결하려는 노력들이 경주되어 왔다.As means for solving this problem, attempts have been made to solve the problems by providing various composition methods as shown in the following prior art documents.
하지만, 특허등록번호 1013228510000에 개시된 뉴캐슬병바이러스, 조류독감 바이러스 증식 억제 조성물들은 단순히 추출물을 만드는 방식이므로 이를 실제 축사등에 적용하기에는 추출물의 기화의 문제로 실제 얻을 수 있는 효과는 유명무실화 되기 때문에 실제 적용하기에는 효과를 얻을 수 없는 한계를 지니고 있다.However, since the Newcastle disease virus and avian influenza virus growth inhibiting compositions disclosed in Patent Registration No. 1013228510000 are simply a method for producing an extract, the effect actually obtained from the problem of vaporization of the extract is not effective for practical application It is not possible to obtain.
또한, 특허등록번호 1014268880000에 인삼 또는 홍삼 추출물로서 항-조류독감 바이러스 조성물의 효과 역시 추출물의 기화현상에 대한 해결책이 없는 바, 이를 실제 축사등에 적용하기에는 무리가 있다.In addition, the effect of the anti-avian influenza virus composition as a ginseng or red ginseng extract in patent registration no. 1014268880000 also has no solution to the vaporization phenomenon of the extract, so that it is difficult to apply it to an actual barn.
기타 특허등록번호 1013173180000, 1008089100000, 1011607430000등 다양한 특허기술이 있지만 이러한 각종 추출물의 조성법만으로는 실제로 축사등에 적용하기에는 기술적 한계를 가지고 있다.There are various patented technologies such as other patent registration numbers 1013173180000, 1008089100000, and 1011607430000. However, the method of producing these various extracts has technical limitations to actually apply to the house or the like.
대부분의 선행기술들은 이러한 현상에 대응하기 위한 항균 기능성을 높인 단순 추출물들의 조성법과 조성법을 이용한 사료조성물에 관련된 기술들만 있을 뿐이다.Most of the prior arts have only the technologies related to the composition and composition of the simple extracts that enhance the antibacterial function to cope with this phenomenon.
본 특허에서 사용하는 미세캡슐화기술은 이미 특허효력이 상실, 범용적으로 사용이 되는 기술로서 기존 기술을 활용하여 본 특허조성물의 조제법에 활용을 하였다.The microencapsulation technology used in this patent has already lost its patent validity and has been widely used in the preparation of the present patent composition by utilizing existing technology as a general use technology.
본 발명은 상술한 바와 같은 종래 기술상의 제반 문제점들을 감안하여 이를 실제 적용할 수 있는 문제를 해결하고자 창출된 것으로, 친환경 미세캡슐화 기술을 이용하여 조류독감, SARS, MERS, 코로나바이러스등에 방제재로서의 효과가 있는 천연허브로 조성한 방제 조성법 및 친환경적인 실질적인 방제 조성물을 제공함에 그 주된 목적이 있다.DISCLOSURE OF THE INVENTION The present invention has been made in view of the above-described problems in the prior art and has been made in order to solve the problem that can be practically applied thereto. The present invention provides an anti-inflammatory effect such as avian influenza, SARS, MERS, And a natural environment-friendly composition for controlling the same.
본 발명은 상기한 목적을 달성하기 위한 수단으로, 조류독감등의 방제재로서의 적합한 허브의 조합과 그 비율을 확정하고, 미세캡슐화에 사용되어 질 허브는 허브의 성질을 100% 활용할 수 있는 에센셜(Essential) 오일 형태로 사용하며 또한 범용 기술인 미세캡슐화의 적용에 있어서의 방법을 구체적으로 제공한다.As a means for achieving the above object, the present invention provides a combination of suitable herbs as an antiseptic agent for avian influenza and the like and a ratio thereof, and an essential herb to be used for microencapsulation is an essential (100% Essential " oil < / RTI > form and also provides a method for the application of microencapsulation, which is a general technique.
본 발명에서 사용하는 오레가노 허브는 이미 국내/외 많은 논문으로서 강력한 항균 작용이 조사되었으며, 조류독감과 같은 인풀루엔자(Influenza)에서의 항-인풀루엔자(Anti-Influenza)로서의 손색없는 특징이 해외 제약저널의 논문에서도 소개가 된바, 오레가노 허브를 주성분으로 하는 제재를 특허하였다.The oregano herb used in the present invention has already been investigated in many domestic and foreign papers for its strong antimicrobial activity and its excellent characteristics as Anti-Influenza in Influenza such as avian influenza It was also introduced in the paper of the pharmaceutical journal and patented the material mainly composed of oregano herb.
본 발명에서 사용하는 허브의 형태는 에센셜(Essential) 오일이며 이 형태가 기본 원료로 적합한 이유는 에센셜 오일은 소독 및 방부 효과가 뛰어나며 100% 순수 자연성분으로 생명력과 치유력을 가지고 있으며 식물 그 자체의 항균효과를 보유하고 있는 식물로부터 직접 추출된 농축액이며 이는 본 특허에서 해결하려는 효과의 극대화를 꾀하는데 매우 유익하다. 또한 보다 높은 효과와 제조상의, 사용상의 편이성을 고려하여 평균 25%(용액 100ml당 용질 g수. 이하 같음) 농축한 오레가노 에센셜 오일을 기본 원료로 사용한다.The form of the herb used in the present invention is Essential oil, and this form is suitable as the basic raw material because essential oil is excellent in disinfection and preservative effect, has 100% pure natural ingredient, has vitality and healing power, This is a concentrate extracted directly from the plant having the effect, which is very beneficial in maximizing the effect to be solved in the present patent. Also, Oregano Essential Oil, which is concentrated to an average of 25% (solubility per 100 ml of solution is equal to or less), is used as a basic raw material in consideration of higher effect and ease of use in manufacturing.
본 발명에 활용되는 기본 허브의 조합과 그 비율은 하기와 같다.The combination of the basic hubs used in the present invention and their ratios are as follows.
25% 농축 25% concentration 오레가노oregano 허브 Herb 에센셜오일Essential Oils : : 로즈마리Rosemary 허브 Herb 에센셜오일Essential Oils : 올리브 오일 = 1: : Olive oil = 1: 0.032:4.560.032: 4.56
오레가노 허브의 성분 중 카바크롤(Carvacrol)의 활동력을 극대화하기 위한 보조제로 올리브 오일을 부가적으로 첨가하며, 로즈마리 허브는 주원료 자체의 방부효과를 거둘 수 있는 용도로 활용이 되며 이들 오일의 자연스러운 혼합을 위하여 계면활성제(Sodium Lauryl Sulfate)를 0.08 비율로 혼합할 수도 있다.As an aid to maximize the activity of carvacrol, olive oil is added additionally, and the rosemary herb is used for the preservative effect of the main ingredient itself, and the natural blending of these oils Sodium Lauryl Sulfate may be mixed in a ratio of 0.08.
25% 농축 오레가노 허브 에센셜오일 : 로즈마리 허브 에센셜오일 : 올리브 오일 : 계면활성제 = 1:0.032:4.56:0.0825% concentrated Oregano Herbal Essential Oil: Rosemary Herbal Essential Oil: Olive Oil: Surfactant = 1: 0.032: 4.56: 0.08
또한 최종 완성될 방역제재의 향과 다른 소정의 목적을 위하여 그 용도에 맞게 스피아민트, 라벤더, 타임, 로즈마리, 자스민, 유칼립투스 에센셜오일등 기능과 향에 따라 취향껏 혼합할 수 있다.Lavender, thyme, rosemary, jasmine, eucalyptus essential oil, and the like depending on the function and flavor of the product to suit the intended use for the purpose of the perfume and the finished product to be finished.
본 발명에 필요한 에센셜 오일의 추출방법은 수증기 증류법, 직접 증류법, 파코레이션법(Percolation), 압착법(Expression), 냉침법(Enfleurage), 유기용제법(Extration)등 모든 방법으로 추출된 에센셜 오일이 다 사용이 가능하다. Essential oil extraction methods necessary for the present invention include extraction of essential oils extracted by all methods such as steam distillation, direct distillation, percolation, compression, enfleurage and extration, It is possible to use it.
본 발명의 오레가노 오일의 미세캡슐화 방법은,In the method of microencapsulating oregano oil of the present invention,
1950년대 미국에서 개발된 기술로서 그 용도에 따라 다양한 방법이 있겠으나 이미 미세캡슐화를 할 수 있는 다양한 장비들도 존재하는 바, 특별한 지식이 필요하지 않으며 다양한 저마다의 특허 방식으로 미세캡슐화를 적용시켜도 무방하다.In the 1950s, the technology developed in the United States has various methods depending on its use, but there are already various devices capable of microencapsulation, so that there is no need of special knowledge and microencapsulation can be applied to various various patenting methods Do.
본 발명을 위해 사용되어진 미세캡슐화 장비는 스위스 BUCHI Labortechnik AG 사의 "Spray Drying Samll (300nm ~ 5μm) BUCHI Encapsultor B-390/B-395 Pro 제품으로 제조 공정은 하기와 같다.(도 1)The microencapsulation equipment used for the present invention is a "Spray Drying Samll (300 nm to 5 μm) BUCHI Encapsultor B-390 / B-395 Pro product of BUCHI Labortechnik AG, Switzerland.
악세사리 : Concentric nozzle system : Shell nozzle 400 μm & core nozzle 150 μm Accessories: Concentric nozzle system: Shell nozzle 400 μm & core nozzle 150 μm
준비물.materials.
1. Polymer : 2.0% (w/v) Na-alginate 믹서를 사용하여 용해 시켜 준비 1. Polymer: prepared by dissolving using 2.0% (w / v) Na-alginate mixer
2. 경화액 : 100 mM CaCl2 containing 0.1% Tween 80 2. Curing solution: 100 mM CaCl2 containing 0.1% Tween 80
3. 캡슐화 물질 : 25% 농축 오레가노 에센셜 오일, 로즈마리 에센셜 오일3. Encapsulated material: 25% concentrated oregano essential oil, rosemary essential oil
4. 증류수 4. Distilled water
제조방법Manufacturing method
1. 물 200 ㎖ 에 Na-alginate 분말 4.0 g 을 넣는다. Na-alginate을 믹서를 사용하여 용해시킨다.1. Add 4.0 g of Na-alginate powder to 200 ml of water. Na-alginate is dissolved using a mixer.
완전히 용해 시켜야하며 발생된 기포는 초음파세척기 혹은 진공을 이용하여 제거 한다. Completely dissolve and remove the generated bubbles using ultrasonic cleaner or vacuum.
2. CaCl2 (dihydrate) 1.47 g을 물 100 mL에 Tween 80 0.1 mL과 함께 넣어 녹인다. 2. Dissolve 1.47 g of CaCl2 (dihydrate) in 100 mL of water with 0.1 mL of Tween 80.
(Tween 80은 경화액의 표면장력을 줄여 캡슐이 경화액에 떨어질 때 캡슐이 터지는 것을 방지 (Tween 80 reduces the surface tension of the curing liquid to prevent the capsule from popping when the capsule falls on the curing liquid.
하기 위해 첨가) Lt; / RTI >
3. Alginate 먼저 Shell 노즐을 통해 주입해야 한다. 안정된 Droplet 줄기를 얻은 후 Core 노즐을3. Alginate should be injected first through Shell nozzle. After obtaining a stable droplet stem,
통해 먼저 25% 농축 오레가노 에센셜 오일의 주입을 시작한다. Core물질이 캡슐되어 경화액으로 Through the first injection of 25% concentrated oregano essential oil will begin. The core material is encapsulated and cured
떨어지는 안정적인 한줄기의 Droplet줄기를 얻기 위해 설정값(주입속도 등)을 일부 조정해야 할 You need to adjust some of your settings (injection rate, etc.) to get a stable, steady drop of droplets.
필요가 있다. There is a need.
4. 생성된 입자는 20분간 CaCl2내에서 더 단단해 진다. 그리고 많은 양의 물로 씻어 낸다.4. The resulting particles are harder in CaCl2 for 20 minutes. Then rinse with plenty of water.
5. 25% 농축 오레가노 에센셜 오일 작업이 끝나면 로즈마리 에센셜 오일로 다시 반복한다.5. 25% concentrated Oregano essential oil Repeat with the essential oils of rosemary after work.
6. 나노사이즈에서 미세캡슐화 적용된 두 에센셜 오일을 상기 기재한 비율대로 혼합한다.6. Microencapsulation in nano-size The two essential oils applied are mixed in the proportions described above.
완성된 방역제재의 전자현미경 사진은 (도 2)와 같이 볼 수 있다. An electron micrograph of the finished anti-fouling material can be seen (Figure 2).
여기서 상기 캡슐소재는 유화력, 피막형성 능력, 유화안전성이 우수하고, 흡수성, 점도가 낮고, The capsule material is excellent in emulsifying power, film-forming ability, emulsion safety, absorbability, low viscosity,
경제적이며, 주원료 물질과 반응성이 적어야 하는 동시에 식품산업에서 허용된 용매에서 용해도가Economical, less reactive with the raw materials, and at the same time the solubility in solvents permitted in the food industry
우수해야 한다. 특히 몰토덱스트린, 아라비아 검, 젤라틴을 사용하는 것이 바람직하다.It should be excellent. In particular, it is preferable to use maltodextrin, gum arabic, and gelatin.
7. 완성된 미세캡슐화 적용된 방역제재는 고농축된 상태이므로 용도에 맞게 적절히 증류수로 희7. Completed microencapsulation The applied anti-fungal agent is highly concentrated,
석을 한다. I will stone.
방역제재로서의 희석비율은 1:50 ~ 1:300 사이이며 병원균의 독성에 따라 그 희석률을 결정한다.The dilution rate as a sanitizer is between 1:50 and 1: 300, and the dilution rate is determined according to the toxicity of the pathogen.
일반적으로 1:100을 기본 희석률로 결정할 수 있다.In general, 1: 100 can be determined as the default dilution.
최종 공정도식은 (도 3)과 같이 정리할 수 있다.The final process equation can be summarized as shown in FIG.
본 발명에 따르면, 친환경 미세캡슐화기술이 적용된 천연허브 추출물은 조류독감, SARS, MERS, 코로나바이러스등의 방역제재로서 효과를 얻을 수 있다.According to the present invention, the natural herbal extract to which the environmentally-friendly microencapsulation technology is applied can be obtained as a preventive agent for avian influenza, SARS, MERS, coronavirus and the like.
또한 해당 용액으로 강력한 천연 항균제, 살균제, 항곰팡이제, 방충제, 탈취제의 효과를 부가적으로 얻을 수도 있다.In addition, the effect of the natural antibacterial agent, fungicide, antifungal, insecticide and deodorant can be additionally obtained with the solution.
(도1) 미세캡슐화 기기
(도2) 미세캡슐화한 원료의 전자현미경 사진
(도3) 전체적 제조 공정(Figure 1) Microencapsulation device
(Fig. 2) Electron micrographs of microencapsulated raw materials
(Fig. 3) Overall manufacturing process
이하, 실시예를 통하여 본 발명을 더욱 상세히 설명하고자 한다. 이들 실시예는 오로지 본 발명을 보다 구체적으로 설명하기 위한 것으로서, 본 발명의 요지에 따라 본 발명의 범위가 이들 실시예에 의해 제한되지 않는다는 것은 본 발명이 속하는 기술 분야에서 통상의 지식을 가진 자에게 있어서 자명할 것이다.Hereinafter, the present invention will be described in more detail with reference to Examples. It is to be understood that the scope of the present invention is not limited by these examples in accordance with the gist of the present invention, and it is to be understood by those skilled in the art that the present invention is not limited thereto It will be obvious.
또한 본 실시예는 쉽게 조류독감 바이러스 및 세포에 접근하기 어려운 사유로 해외에서 이루어진 실시예를 소개한다.This embodiment also introduces examples made overseas because of difficulty in accessing avian influenza virus and cells.
실시예Example
테스트 준비Test preparation
카바크롤(Carvacrol)이 풍부하다고 알려진 오레가노 에센셜 오일을 4개의 비교군으로 준비를 한다.Prepare the oregano essential oil, rich in Carvacrol, with four comparable groups.
ORE 1 : 카바크롤 비율 75~85%, 오레가노:올리브오일 혼합비 25:75ORE 1: Carbacol ratio 75-85%, oregano: olive oil mixture ratio 25:75
ORE 2 : 카바크롤 비율 93%, 오레가노:올리브오일 혼합비 18:82ORE 2: 93% of carbalkol ratio, oregano: olive oil mixture ratio 18:82
ORE 3 : 카바크롤 비율 80%, 오레가노:올리브오일 혼합비 40:60ORE 3: 80% carbabaccol ratio, oregano: olive oil mixture ratio 40:60
ORE 4 : 카바크롤 비율 -, 오레가노:올리브오일 혼합비 100:0ORE 4: carbacrole ratio -, oregano: olive oil mixture ratio 100: 0
세포와 바이러스Cells and viruses
MDCK Canine 콩팥 세포, A549 폐세포(from ATCC)MDCK Canine kidney cells, A549 lung cells (from ATCC)
Influenza (H1N1) (from BC Centre for Disease Control in Vancouver)Influenza (H1N1) (from BC Center for Disease Control in Vancouver)
분석법Analysis method
표준 분석법 : Vimalanathan et al., 2005, Pleschka et al.,2009Standard method: Vimalanathan et al., 2005, Pleschka et al., 2009
세포분석법 : XTT (ATCC Manassas.,VA,USA)Cell analysis: XTT (ATCC Manassas, Va., USA)
결과result
항바이러스 효과Antiviral effect
초기 모든 오일샘플은 인플루엔자에 대한 항균력을 보여주고 있다.All early oil samples show the antimicrobial activity against influenza.
표는 100μl/ml 농축도에서 각 오일 샘플의 H1N1에 대한 억제효과를 보여주고 있다.The table shows the inhibitory effect of each oil sample on H1N1 at a concentration of 100 μl / ml.
고밀도 바이러스에 대한 항바이러스 효과Antiviral effect against high density virus
10^5 pfu 의 고밀도 바이러스를 각 비교군 용액에 배양하여 바이러스의 억제력을 확인한 결과 대부분의 용액에서 100% 억제력을 보이고 있다.10 ^ 5 pfu of high density virus was cultivated in each comparative group solution to confirm the inhibitory effect of virus. As a result, it showed 100% inhibition ability in most solutions.
허브용액 독성검사Herbal solution toxicity test
비교군 용액을 XTT 방식에 의하여 사람의 콩팥, 폐 세포에 적용 후 각 세포의 생존력을 농도별로 확인한 결과 비교군 2의 희석률이 가장 인체에 무해한 비율임을 알 수가 있다.When the comparative group solution was applied to human kidney and lung cells by XTT method, the viability of each cell was checked by concentration, and it was found that the dilution ratio of comparative group 2 was the most harmless ratio to human body.
본 실험의 기준으로 특허의 배합비율은 결정이 되어 있다.As a standard of this experiment, the compounding ratio of the patent is decided.
Claims (2)
The combination of the herb that can be effective as a disinfectant / emollient and its ratio and the microencapsulation technology that can actually commercialize the effect of the herb are used to determine the dilution ratio of the final microencapsulated raw material Phosphorus preparations can be used as antiseptic / antidote to infectious diseases such as avian influenza, SARS, MERS and coronavirus.
상기 미세캡슐화 단계에서, 미세캡슐화되는 기능성 조성물은
25% 농축 오레가노 허브 에센셜오일 : 로즈마리 허브 에센셜오일 : 올리브 오일 = 1: 0.032:4.56
이며, 최종 혼합된 농축 원액의 희석 비율은 1:50 ~ 1:100 으로 하는 조류독감, SARS, MERS, 코로나바이러스등의 전염병에 대한 방역/방제재로서 사용가능한 방제재 조제법.The method according to claim 1,
In the microencapsulation step, the functional composition to be microencapsulated is
25% concentrated Oregano Herbal Essential Oil : Rosemary Herbal Essential Oil : Olive Oil = 1: 0.032: 4.56
And the dilution ratio of the final mixed concentrate is 1:50 to 1: 100, which can be used as an antiseptic / disinfectant for infectious diseases such as avian influenza, SARS, MERS and coronavirus.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020160184595A KR20180079136A (en) | 2016-12-31 | 2016-12-31 | Compositions for Anti-Avian influenza virus, SARS, MERS, Coronavirus by micro encapsulized natural herbs |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020160184595A KR20180079136A (en) | 2016-12-31 | 2016-12-31 | Compositions for Anti-Avian influenza virus, SARS, MERS, Coronavirus by micro encapsulized natural herbs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20180079136A true KR20180079136A (en) | 2018-07-10 |
Family
ID=62916301
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020160184595A KR20180079136A (en) | 2016-12-31 | 2016-12-31 | Compositions for Anti-Avian influenza virus, SARS, MERS, Coronavirus by micro encapsulized natural herbs |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20180079136A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022029060A1 (en) * | 2020-08-07 | 2022-02-10 | Jean Angelidis | Virucidal decontaminating composition |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20000001148A (en) * | 1998-06-09 | 2000-01-15 | 최영신 | Essential oil composition having functions of antibiosis and antifungus |
| KR20060108163A (en) * | 2005-04-12 | 2006-10-17 | 한국생명공학연구원 | Antiviral composition comprising plant extracts |
| JP2007528285A (en) * | 2003-05-11 | 2007-10-11 | ベン グリオン ユニバーシティ オブ ザ ネゲブ リサーチ アンド ディベロップメント オーソリティ | Encapsulated essential oil |
| KR20080106181A (en) * | 2006-02-15 | 2008-12-04 | 보타노캡 엘티디. | Applications of microencapsulated essential oils |
| WO2011045643A1 (en) * | 2009-10-14 | 2011-04-21 | Vitiva D.D. | Preservation of non-alcoholic beverages and functional waters against spoilage by bacteria of the genus alicyclobacillus |
| JP2014507441A (en) * | 2011-02-25 | 2014-03-27 | エイド・ファルマ | Nano-encapsulation of essential oils to prevent or treat infections alone or with antibiotics |
-
2016
- 2016-12-31 KR KR1020160184595A patent/KR20180079136A/en not_active Application Discontinuation
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20000001148A (en) * | 1998-06-09 | 2000-01-15 | 최영신 | Essential oil composition having functions of antibiosis and antifungus |
| JP2007528285A (en) * | 2003-05-11 | 2007-10-11 | ベン グリオン ユニバーシティ オブ ザ ネゲブ リサーチ アンド ディベロップメント オーソリティ | Encapsulated essential oil |
| KR20060108163A (en) * | 2005-04-12 | 2006-10-17 | 한국생명공학연구원 | Antiviral composition comprising plant extracts |
| KR20080106181A (en) * | 2006-02-15 | 2008-12-04 | 보타노캡 엘티디. | Applications of microencapsulated essential oils |
| WO2011045643A1 (en) * | 2009-10-14 | 2011-04-21 | Vitiva D.D. | Preservation of non-alcoholic beverages and functional waters against spoilage by bacteria of the genus alicyclobacillus |
| JP2014507441A (en) * | 2011-02-25 | 2014-03-27 | エイド・ファルマ | Nano-encapsulation of essential oils to prevent or treat infections alone or with antibiotics |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022029060A1 (en) * | 2020-08-07 | 2022-02-10 | Jean Angelidis | Virucidal decontaminating composition |
| FR3113223A1 (en) * | 2020-08-07 | 2022-02-11 | Jean Angelidis | Virucidal decontaminating composition |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| São Pedro et al. | The use of nanotechnology as an approach for essential oil-based formulations with antimicrobial activity | |
| Liang et al. | Physical and antimicrobial properties of peppermint oil nanoemulsions | |
| CN104353401B (en) | Condense multinuclear plants essential oil slow-release microcapsule and manufacture method, purposes again | |
| KR20160079473A (en) | Preparation method of cleaning or disinfecting composition having antiviral activity by containing green tea extract as active component | |
| KR20180069278A (en) | Insect repellent composition and preparing method thereof | |
| CN107823602A (en) | A kind of Chinese herbal medicine essential oil antibacterial microcapsule and preparation method thereof | |
| Ishfaq et al. | Biochemical and pharmacological applications of essential oils in human health especially in cancer prevention | |
| CN104906185A (en) | Chinese herbal medicine essential oil microcapsule and preparation method and application thereof | |
| CN103977443A (en) | Folium artemisiae argyi extract air freshener for air sterilization and mosquito repelling | |
| Paul et al. | Essential oils: A review on their salient biological activities and major delivery strategies | |
| RU2012148727A (en) | NEW COMPOSITIONS OF ACTIVE (S) INGREDIENT (S) OF PLANT ORIGIN OR THEIR SYNTHETIC ANALOGUES OR CONTAINING THEIR EXTRACT (S) OF PLANT ORIGIN AND LECITHIN | |
| CN109601722A (en) | A kind of preparation method of lauric monoglyceride coating plants essential oil | |
| Adeyemi et al. | Polymeric nanoparticles for enhanced delivery and improved bioactivity of essential oils | |
| JP7286117B2 (en) | Compositions for the manufacture of products for public health | |
| Basha et al. | Properties and mechanism of antimicrobial agents from plant-derived essential oils | |
| KR20180079136A (en) | Compositions for Anti-Avian influenza virus, SARS, MERS, Coronavirus by micro encapsulized natural herbs | |
| CN105662956A (en) | Preparation method of hand sanitizer for skin disinfection | |
| KR20160079459A (en) | Cleaning or disinfecting composition having antiviral activity by containing green tea extract as active component | |
| CN104026150B (en) | Composite liquid for preventing and killing avian influenza viruses and preparation method and application thereof | |
| Tomanić et al. | Review of trends in essential oils as alternatives to antibiotics in bovine mastitis treatment | |
| El-Gebaly et al. | Combination of nanoparticles (NPs) and essential oils (EOs) as promising alternatives to non-effective antibacterial, antifungal and antiviral agents: A review | |
| Pandey et al. | Recent advances in delivering free or nanoencapsulated Curcuma by-products as antimicrobial food additives | |
| Baldim et al. | Encapsulation of essential oils in lipid-based nanosystems | |
| CN104288014A (en) | Herbal floral water and preparation method thereof | |
| Pollini et al. | Combining inorganic antibacterial# nanophases and essential oils recent findings and prospects |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E601 | Decision to refuse application |